MuratVeyselKalayogluMDPhD, MBA

Physician

Dr. Kalayoglu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Engineered cell therapies for cancer and autoimmune, respiratory and inflammatory diseases

Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 2001 - 2004
University of Wisconsin School of Medicine & Public HealthClass of 2000

PubMed

38 citations
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-rand...
Volkan Granit, Michael Benatar, Metin Kurtoglu, Miloš D Miljković, Nizar Chahin
The Lancet. Neurology. 2023-07-01
26 citations
Tryptophan metabolism in chronic inflammatory lung disease.
Keith C. Meyer, R A Arend, Murat V. Kalayoglu, N S Rosenthal, Gerald I. Byrne
The Journal of Laboratory and Clinical Medicine. 1995-12-01
148 citations
A Chlamydia pneumoniae Component That Induces Macrophage Foam Cell Formation Is Chlamydial Lipopolysaccharide
Murat V. Kalayoglu, Gerald I. Byrne
Infection and Immunity. 1998-11-01

Dr. Murat Kalayoglu, President & CEO, Cartesian Therapeutics: The Leader in RNA Cell TherapyMay 31st, 2022
Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple MyelomaJanuary 25th, 2022
Cartesian Therapeutics Strengthens Leadership Team with Hire of Miloš Miljković, M.D., as Chief Medical OfficerSeptember 28th, 2021
Join now to see all